pretickt

Is ELV a good stock to buy?

Elevance Health Inc. · end-of-day data as of Nov 13, 2026

Elevance Health
ELV · $92.84B
$429.690.0%
Nov 13, 2026 · close
$400$450SepOctNov9:3016:003 months +8.4%Nov 13 · close
▲ 6
  • PT$461.56 +7.4%
  • ConsensusBuy · 22
  • P/E vs sector-43.1%
  • FCF yield+7.0%
  • MAs4 of 4
  • Sector▲ +15.9%
Neutral
  • Earnings in75d
  • P/E18.3x
  • RSI55
  • Support-2.3%
  • Resistance+2.3%
  • Off 52w high-4.7%
  • Volume0.6x
  • Bollingerupper half
  • News0.00
  • Trendsideways
  • 52w range$275–$451
  • ATR+2.9%
  • Off ATH-24.3%
  • MA20×50↓ in ~26d
▼ 3
  • P/E vs own+21.8%
  • Insiders-$5.23M
  • MACD-0.33

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Elevance Health a good stock to buy?

Elevance Health is strong on 4 of the 5 questions about the business. The price is about usual: 18.3 times its earnings, near its 3-year median of 16.8 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage hard to copy
  3. Economics profits steady
  4. Execution delivers
  5. Fragility sturdy
  6. Price about usual
DemandDo people want more of what it sells?growing

ELV sales growth revenue growth

+8%a year, for the last 3 years

Elevance Health's sales grew 8% a year for 3 years, to $199B in fiscal 2025.

ELV analysts' forecast revenue estimates

0%the sales they expect next fiscal year, on the last

Analysts expect Elevance Health's sales to grow 0% to $200B in fiscal 2026 (12 analysts).

ELV competitors

pretickt analysis+4%its sales in 12 months, on a year before

Elevance Health's sales grew 4% in the 12 months to Sep 30, 2026, slower than Humana (+22%), Cigna (+7%), CVS Health (+7%) and Centene (+5%).

Advantage moatIs it hard to copy?hard to copy

ELV margin on each sale gross margin

37%left after making the product

Elevance Health kept 37% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 14%.

EconomicsDoes it make good money?profits steady

ELV cash generated free cash flow

$6.51Bcash left after investing, last 12 months

Elevance Health generated $6.51B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

ELV profit per share

-2%in its last fiscal year

Elevance Health's earnings per share fell 2% in fiscal 2025, to $25.12.

ExecutionDoes it deliver what it promises?delivers

ELV earnings vs estimates

7 of 8quarters above the analysts' estimate

Elevance Health beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 21, 2026.

ELV insider selling

-$4.74Msold, net, by its executives in 12 months

Elevance Health's executives and directors sold a net $4.74M of shares in the 12 months to Nov 13, 2026 ($6.98M sold, $2.24M bought).

ELV number of employees

-7%fewer people in a year

Elevance Health had 97,100 employees at the end of fiscal 2025, 7% fewer than a year before.

Fragility risksCould something break it?sturdy

ELV financial health Altman Z-score

3.1Altman Z-score, safe above 3

Elevance Health's Altman Z-score is 3.1 (Nov 13, 2026), above 3, where the safe zone starts.

ELV quality checks Piotroski score

7 of 9checks passed

Elevance Health passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets and sales for its assets.

ELV shareholders institutional ownership

pretickt analysis
  • Vanguard9.3% ▼
  • BlackRock8.7% ▼
  • State Street4.7% ▲
1,681institutions hold it; the largest sold shares

1,681 institutions hold 92% of Elevance Health's shares (Jun 30, 2026); State Street added shares that quarter, Vanguard and BlackRock sold some.

Price valuationIs the price reasonable?about usual

ELV price vs profit P/E ratio

18.3×a year's earnings

Elevance Health's P/E ratio is 18.3 (Nov 13, 2026), near its 3-year median of 16.8.

ELV price vs competitors

pretickt analysis18.3×a year's earnings, against its competitors

Investors pay 18.3 times Elevance Health's earnings (Nov 13, 2026), more than for Cigna (13.1) and CVS Health (10.4), less than for Humana (43.8) and Centene (24.4).

ELV analysts' target price target

+7%to their average target

Analysts' average price target for Elevance Health is $462, 7% above the Nov 13, 2026 close of $429.69.

ELV growth priced in fair value

pretickt analysis+2%a year, for ten years, to be worth the price

At $429.69 a share, Elevance Health's free cash flow must grow about 2% a year for ten years to be worth the price (Nov 13, 2026).

What is Elevance Health's P/E ratio?

Elevance Health's P/E ratio is 18.3 (Nov 13, 2026), near its 3-year median of 16.8. Investors pay 18.3 times Elevance Health's earnings (Nov 13, 2026), more than for Cigna (13.1) and CVS Health (10.4), less than for Humana (43.8) and Centene (24.4).

Who are Elevance Health's biggest competitors?

pretickt compares Elevance Health with Cigna, CVS Health, Humana and Centene. Elevance Health's sales grew 4% in the 12 months to Sep 30, 2026, slower than Humana (+22%), Cigna (+7%), CVS Health (+7%) and Centene (+5%).

Are insiders selling Elevance Health stock?

Elevance Health's executives and directors sold a net $4.74M of shares in the 12 months to Nov 13, 2026 ($6.98M sold, $2.24M bought).

Who owns Elevance Health stock?

1,681 institutions hold 92% of Elevance Health's shares (Jun 30, 2026); State Street added shares that quarter, Vanguard and BlackRock sold some.

How many employees does Elevance Health have?

Elevance Health had 97,100 employees at the end of fiscal 2025, 7% fewer than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.